

## Monoclonal Antibody Treatment Available for High-Risk COVID-19 Patients

While vaccines remain our best protection against COVID-19, more of your patients may be eligible for COVID-19 monoclonal antibody treatment. According to the Florida Department of Health, monoclonal antibody treatment can prevent severe illness, hospitalization and death in high-risk patients who have contracted or been exposed to COVID-19.

Individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19 are now eligible for monoclonal antibody treatment under the Food and Drug Administration's emergency use authorization. Vaccination status does not matter. **Physician referral is not required.** In addition to traditional outpatient settings, treatment is also available at any of the State of Florida [monoclonal antibody treatment sites](#). **Please note:** Non-participating providers are required to obtain authorizations, per normal business practice. Commercial HMO members do not have coverage for treatment from non-participating providers without an authorization.

### Billing Information

For Commercial plan patients, if your facility provides monoclonal antibody treatment for COVID-19, please bill Florida Blue for covered infusion therapy for the administration only using the appropriate CPT code below. The product should not be billed as it is provided by the government. Your Florida Blue patients will be responsible for their normal cost share for the administration. You can check patient eligibility and benefits through Availity<sup>®1</sup> on [availity.com](#).

For Medicare Advantage patients, the Centers for Medicare & Medicaid Services (CMS) has instructed providers to bill Original Medicare for administration of the monoclonal infusion. The product should not be billed as it is provided by the government. There are billing edits in place to deny these services accordingly if billed to Florida Blue Medicare.

### State of Florida Monoclonal Antibody Treatment Sites

In addition to traditional outpatient settings, treatment is also available at any of the [State of Florida monoclonal antibody treatment sites](#) to individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19. Vaccination status does not matter. **Physician referral is not required.** The State has indicated that there will be no cost for the treatment, but they may bill the member's plan if insurance information is provided. If any claims are received, they will be processed per the member's normal benefits.

### Eligibility Criteria for Monoclonal Antibody Therapy

According to the Florida Department of Health, individuals 12 years and older who are high-risk and who have contracted or been exposed to COVID-19 are eligible for this treatment. High-risk factors include:

- Age 65 and older
- Cardiovascular disease or hypertension
- Chronic kidney disease
- Chronic lung disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Neurodevelopmental disorders
- Obesity
- Pregnancy
- Sickle cell disease
- Having a medical-related technological dependence (i.e., tracheostomy, gastrostomy or positive pressure ventilation not related to COVID-19)

<sup>1</sup>Availity, LLC is a multi-payer joint venture company. For more information or to register, visit [availity.com](#). Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

### Vaccines Still the Most Effective Way to Prevent Serious Illness/Death

Both the monoclonal antibody treatment and vaccines have received emergency use authorization from the FDA. The Pfizer-BioNTech vaccine has received full FDA approval for use in people age 16 and over. According to [floridahealthcovid19.gov](http://floridahealthcovid19.gov), in clinical trials, monoclonal antibody treatment showed a 70 percent reduction in hospitalization and death.

COVID-19 vaccines are highly effective in **preventing serious consequences of COVID-19**, including severe disease, hospitalization, and death. We continue to support ongoing vaccination efforts against COVID-19, as this is critical to ending the pandemic.

### CPT Codes for Monoclonal Antibody Therapy

Please refer to this chart for the codes to use for monoclonal antibody therapy. This chart was created by CMS, and you can find the most [up-to-date version here](#), which includes additional information denoted in brackets.

HCPCS Code	HCPCS Short Descriptor	Labeler Name	National Payment Allowance Effective for Claims with DOS on or after 05/6/2021	Effective Dates
<b>M0239</b>	Bamlanivimab-xxxx infusion	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021
<b>M0240</b>	Casiri and imdev repeat	Regeneron	\$450.00 <sup>[3]</sup>	07/30/2021 – TBD
<b>M0241</b>	Casiri and imdev repeat hm	Regeneron	\$750.00 <sup>[3]</sup>	07/30/2021 – TBD
<b>M0243</b>	Casirivi and imdevi inj	Regeneron	\$450.00 <sup>[3]</sup>	11/21/2020 – TBD
<b>M0244</b>	Casirivi and imdevi inj hm	Regeneron	\$750.00 <sup>[3]</sup>	05/06/2021 – TBD
<b>M0245</b>	Bamlan and etesev infusion	Eli Lilly	\$450.00 <sup>[3]</sup>	02/09/2021 – TBD
<b>M0246</b>	Bamlan and etesev infus home	Eli Lilly	\$750.00 <sup>[3]</sup>	05/06/2021 – TBD
<b>M0247</b>	Sotrovimab infusion	GSK	\$450.00 <sup>[3]</sup>	05/26/2021 – TBD
<b>M0248</b>	Sotrovimab inf, home admin	GSK	\$750.00 <sup>[3]</sup>	05/26/2021 – TBD
<b>M0249</b>	Adm Tocilizu COVID-19 1st	Genentech	\$450.00 <sup>[3]</sup>	06/24/2021 - TBA
<b>M0250</b>	Adm Tocilizu COVID-19 2nd	Genentech	\$450.00 <sup>[3]</sup>	06/24/2021 - TBA
<b>Q0239</b>	Bamlanivimab-xxxx	Eli Lilly	Code not active during this time period	11/10/2020 – 04/16/2021

<sup>1</sup>Availity, LLC is a multi-payer joint venture company. For more information or to register, visit [availity.com](http://availity.com). Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

<b>Q0240</b>	Casirivi and imdevi 600mg	Regeneron	\$0.010 <sup>[1]</sup>	07/30/2021 – TBD
<b>Q0243</b>	Casirivimab and imdevimab	Regeneron	\$0.010 <sup>[1]</sup>	11/21/2020 – TBD
<b>Q0244</b>	Casirivi and imdevi 1200 mg	Regeneron	\$0.010 <sup>[1]</sup>	06/03/2021 – TBD
<b>Q0245</b>	Bamlanivimab and etesevima	Eli Lilly	\$0.010 <sup>[1]</sup>	02/09/2021 – TBD
<b>Q0247</b>	Sotrovimab	GSK	\$2,394.00	05/26/2021 – TBD
<b>Q0249</b>	Tocilizumab for COVID-19	Genentech	\$6.57	06/24/2021 - TBA